-
Topotecan (SKF104864) for Cancer Research
2026-09-11
Topotecan (SKF104864) is a practical topoisomerase I perturbation tool for linking DNA replication stress to proliferation loss and apoptosis. This workflow-focused guide covers glioma, pediatric solid tumor, combination, and recurrent SCLC research models, with concentration planning and troubleshooting advice.
-
ALDH2 Activators for Myocardial Ischemia: Z17 Study
2026-09-10
The reference study reports a triazole-based aldehyde dehydrogenase 2 (ALDH2) activator series developed to address the limited solubility and activity of earlier compounds. Its lead, Compound Z17, combined strong ALDH2 activation with improved cardiac and biochemical outcomes in a mouse myocardial ischemia–reperfusion model, while remaining an early-stage preclinical candidate.
-
Resiquimod (R-848): Spatial Logic in Tumor Ablation
2026-09-10
Resiquimod (R-848) links TLR7/8 biology with localized chemo-immunomodulation after thermal ablation. This article explains how spatial delivery, timing, and causal controls improve interpretation of innate immune response modulation in translational tumor models.
-
2-NBDG Glucose Uptake Assay Kit for HCC Research
2026-09-09
Map glucose transporter activity alongside sorafenib response with a rapid, non-radioactive fluorescence workflow. The 2-NBDG Glucose Uptake Assay Kit adds single-cell and 96-well compatibility to cancer metabolism studies while phloretin provides a built-in specificity control.
-
YM 58483 (BTP2): Reading SOCE Signal Logic
2026-09-09
YM 58483 (BTP2) is a powerful tool for dissecting store-operated calcium entry across immune and fibrosis models. This article explains how to interpret SOCE blockade mechanistically, using ORAI2-linked postirradiation salivary fibrosis as a case study in experimental design.
-
Filipin III and Cholesterol Homeostasis
2026-09-08
Filipin III is a polyene macrolide antibiotic for resolving membrane cholesterol organization rather than simply measuring total sterol. This article connects its imaging chemistry with the CAV1–cholesterol homeostasis axis in MASLD and shows how to interpret membrane signals alongside transporter, stress, and cell-death assays.
-
CHI3L1-IN-5: Astrocyte Aβ Clearance Workflows
2026-09-08
CHI3L1-IN-5, also called Compound Z17, combines selective CHI3L1 inhibition with functional assays for astrocyte Aβ uptake, lysosomal recovery, and NF-κB suppression. This workflow-focused guide explains how to model CHI3L1-driven dysfunction, select orthogonal readouts, and troubleshoot variability in Alzheimer’s disease research.
-
From DNA Synthesis to Smarter Nucleic Acid Delivery
2026-09-07
A translational perspective on how standardized dNTP inputs can strengthen DNA workflows while clarifying the separate biological bottlenecks that govern lipid nanoparticle trafficking.
-
Tolazoline for α2-Adrenergic Pathway Assays
2026-09-07
Tolazoline supports concentration-resolved studies of α2-adrenergic signaling in airway smooth muscle and pancreatic islets. Its ability to influence both receptor signaling and ATP-sensitive potassium channels makes it useful for mechanism-focused workflows, provided receptor and channel effects are separated experimentally.
-
Poly (I:C) for Dose-Resolved Innate Immunity
2026-09-05
Poly (I:C), a synthetic double-stranded RNA analog, can convert innate immune stimulation into a structured dose-response experiment. This article connects TLR3 biology with recent dose-dependent antiviral findings and practical assay design.
-
Epinephrine Bitartrate: Adrenergic Research Guide
2026-09-04
Epinephrine Bitartrate is a non-selective adrenergic receptor agonist for receptor signaling, cell-function, cardiovascular disease research, and related translational studies. Its strongest quantitative benchmark is a canine comparison showing rapid plasma exposure after intranasal administration, but the result does not establish human dosing or clinical equivalence.
-
PRDX6–GPX4 Control of Ferroptosis
2026-09-04
Hu et al. identify PRDX6 as a dual regulator of ferroptosis resistance: it hydrolyzes peroxidized phospholipids and promotes GPX4 recruitment to damaged membranes through a C47-dependent disulfide interaction. Combining PRDX6 inhibition with ferroptosis inducers increases lipid peroxidation and suppresses tumor growth, although the findings require further validation across cancer types and treatment settings.
-
Multianimal MRI for Pancreatic Tumor Monitoring
2026-09-03
Kempinska et al. describe a four-chamber MRI workflow that images up to four KPC mice in one acquisition while preserving high-resolution anatomical assessment of pancreatic tumors. The protocol reduces imaging burden and supports enrollment, longitudinal monitoring, and proof-of-concept evaluation of gemcitabine treatment in a clinically relevant pancreatic ductal adenocarcinoma model.
-
Protease Inhibitor Cocktail for Phosphoproteomics
2026-09-03
Protease Inhibitor Cocktail EDTA-Free helps preserve signaling proteins and labile phosphoproteins during cell and tissue lysis. This article connects pre-analytical protease control with mechanistic interpretation of p53-mutant lymphoma studies and sensitive downstream assays.
-
Anagliptin: A Causal Map for Vascular Assays
2026-09-02
Anagliptin (SK-0403) is more than a DPP-4 inhibitor in vascular research. This guide translates rabbit aortic-ring evidence into a practical framework for separating Kv channel modulation, SERCA pump regulation, and incretin-linked hypotheses.